Defined by our collaborative and innovation-first culture, OmniaBio is a leader in cell and gene therapy (CGT) manufacturing. With deep technical expertise and experience seated within a thriving CGT ecosystem, we accelerate progress through the entire product lifecycle – from development through to clinical and ultimately commercial manufacture and launch.
Your Idea, Our Expertise
As a focused CDMO in the cell and gene therapy space, we have extensive knowledge and expertise in the field. With our leading cell therapy platforms in iPSC, lentiviral vectors and immunotherapy, we are advancing the science of cell and gene therapies and unlocking their medicinal potential.
Offering the latest technologies in development and manufacturing for CAR T, NK, and other immune cell types
Enabling end-to-end support and a fully integrated platform for Lentivirus production
Accelerating iPSC manufacturing
More Than a Facility
An Ecosystem of CGT-Focused Capabilities
OmniaBio is the latest addition to a vibrant CGT ecosystem. Launched through the technical excellence and established infrastructure of CCRM, the focus of OmniaBio spans from preclinical, process and analytical development through to commercial manufacturing. With deep expertise in iPSC, lentiviral vector (LVV) and immune cell-based therapeutic scale-up, we are focused on the success of next-generation therapeutics from early clinical stage through to launch, all within one organization. Our consolidated offering saves you time and reduces the risk of transferring your products for launch and commercialization.